The first healthcare product of Alnapharm is the dietary supplement OSVALIN®. OSVALIN® is a unique silicon preparation containing hydrolyzed, colloidal silicon dioxide in the highest possible concentration.
Psoriasis is a chronic, incurable dermatological disease. The prevalence of psoriasis is 1.5 to 2% of the population in the industrialized nations. About 80% of the patients suffer from psoriasis vulgaris. Psoriasis vulgaris (psoriasis) represents a frequent and usually chronically progressing dermatological disease. Psoriasis is incurable hence, a permanent treatment is necessary.
Most of the patients use cream products to treat their Psoriasis affected skin. In addition to treatment, patients use individual skin care products to maintain the skin and keep it smooth. These additional costs for individual care products differs in price and causes a high financial burden. Alnapharm is currently developing the skin crème for the treatment of Psoriasis.